To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

NCT04796922 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped This study was withdrawn due to a business decision.

Conditions

Follicular Lymphoma ( FL)
Marginal Zone Lymphoma (MZL)

Interventions

DRUG: parsaclisib
DRUG: rituximab
DRUG: obinutuzumab

Sponsor

Incyte Corporation